Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC.

IF 3.4 2区医学 Q2 ONCOLOGY

BMC Cancer Pub Date : 2024-11-21 DOI:10.1186/s12885-024-13210-9

Armando Santoro, Garrido Pilar, Daniel S W Tan, Jon Zugazagoitia, Frances A Shepherd, Alessandra Bearz, Fabrice Barlesi, Tae Min Kim, Tobias R Overbeck, Enriqueta Felip, Can Cai, Simantini Eddy, Tracey McCulloch, Eric S Schaefer

引用次数: 0

查看原文本刊更多论文

更正：斯帕妥珠单抗联合铂双化疗与或不联合卡那珠单抗治疗未选择 PD-L1 的转移性 NSCLC 患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Cancer 医学-肿瘤学

CiteScore

6.00

自引率

2.60%

发文量

1204

审稿时长

6.8 months

期刊介绍： BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.